ID: ALA5092929

Max Phase: Preclinical

Molecular Formula: C17H9ClFN3O2S2

Molecular Weight: 405.86

Molecule Type: Unknown

Representations

Canonical SMILES:  O=C(Nc1cccc(F)c1)c1sc(=S)n2c1[nH]c(=O)c1ccc(Cl)cc12

Standard InChI:  InChI=1S/C17H9ClFN3O2S2/c18-8-4-5-11-12(6-8)22-14(21-15(11)23)13(26-17(22)25)16(24)20-10-3-1-2-9(19)7-10/h1-7H,(H,20,24)(H,21,23)

Standard InChI Key:  UZLWAHKMJSQPJM-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 405.86

Molecular Weight (Monoisotopic): 404.9809

AlogP: 4.62

#Rotatable Bonds: 2

Polar Surface Area: 66.37

Molecular Species: NEUTRAL

HBA: 5

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 5

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 9.40

CX Basic pKa:

CX LogP: 4.22

CX LogD: 4.22

Aromatic Rings: 4

Heavy Atoms: 26

QED Weighted: 0.48

Np Likeness Score: -2.05

References

1. Liang X, Sun C, Li C, Yu H, Wei X, Liu X, Bao W, Shi Y, Sun X, Khamrakulov M, Yang C, Liu H..  (2021)  Identification of Novel Fused Heteroaromatics-Based MALT1 Inhibitors by High-Throughput Screening to Treat B Cell Lymphoma.,  64  (13.0): [PMID:34181850] [10.1021/acs.jmedchem.1c00466]

Source

Source(1):

• Scientific Literature